UCB Acquires Candid Therapeutics for $2.2 Billion
Belgian pharmaceutical giant UCB has agreed to acquire privately held biotech firm Candid Therapeutics in a deal valued up to $2.2 billion, with an initial payment of $2 billion and additional milestone-based payments. The acquisition is expected to close between the end of Q2 and start of Q3 2026 after regulatory approvals.
Tickers: $UCB